Close

Form 8-K JOHNSON & JOHNSON For: Jun 09

June 9, 2015 5:11 PM EDT





UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): June 9, 2015


 
(Exact name of registrant as specified in its charter)
 

New Jersey
I-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933
 
(Address of Principal Executive Offices)  (Zip Code)
 
Registrant's telephone number, including area code: 732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 










Item 5.02(d).  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The company announced on June 9, 2015 that its Board of Directors has appointed Mary Beckerle, Ph.D., Chief Executive Officer and Director of Huntsman Cancer Institute at the University of Utah, as a Director of Johnson & Johnson. Dr. Beckerle will serve on the Board’s Science, Technology & Sustainability Committee. As a non-employee director of the company, Dr. Beckerle will receive compensation as described in the “Director Compensation” section of the company's 2015 Proxy Statement.  The company's press release announcing the appointment is attached to this Report as Exhibit 99.1.

Item 9.01    Financial Statements and Exhibits.
 
(d)    Exhibits.

Exhibit No.      Description

99.1        Press Release dated June 9, 2015.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


 
 
Johnson & Johnson
(Registrant)
 
June 9, 2015
 
By:
/s/ Lacey P. Elberg
 
 
 
 
Lacey P. Elberg
Assistant Secretary
 


















Exhibit 99.1
Press Contacts:
Ernie Knewitz
 
Amy Jo Meyer
 
 
(732) 524-6623
 
(732) 524-6678
 
 
(917) 697-2318 (M)
 
(908) 616-6250 (M)
 
Investor Contacts:
Louise Mehrotra
 
 
 
 
(732) 524-6491
 
 
 


For Immediate Release

CEO and Director of Huntsman Cancer Institute Dr. Mary Beckerle Joins
Johnson & Johnson Board of Directors
New Brunswick, N.J. (June 9, 2015) - Johnson & Johnson (NYSE: JNJ) announced today that its Board of Directors has appointed Mary Beckerle, Ph.D., Chief Executive Officer and Director of Huntsman Cancer Institute at the University of Utah, as a Director of Johnson & Johnson. Dr. Beckerle will serve on the Board’s Science, Technology & Sustainability Committee.
Dr. Beckerle has served as CEO and Director of Huntsman Cancer Institute since 2006, and she was appointed in 2009 to an additional key health sciences leadership role as Associate Vice President for Cancer Affairs at the University of Utah. She joined the faculty of the University of Utah in 1986, and is a distinguished professor of biology and oncological sciences, holding the Ralph E. and Willia T. Main Presidential Professorship.
“Dr. Beckerle’s expertise in scientific research and organizational management in the health care arena will be invaluable as a member of our Board of Directors,” said Alex Gorsky, Chairman and CEO of Johnson & Johnson. “Her commitment to the needs of patients is directly aligned with Our Credo and mission, and she is a welcome addition to the Johnson & Johnson Board.”
As an active participant in national and international scientific affairs, Dr. Beckerle has served on the NIH Advisory Committee to the Director and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on the Scientific Review Board of the Howard Hughes Medical Institute and the Scientific Advisory Boards of the National Center for Biological Sciences at the Tata Institute of Fundamental Research in India and the Mechanobiology Institute in Singapore. Dr. Beckerle is also currently on the Board of Directors of the American Association for Cancer Research, the Coalition for Life Sciences and the Huntsman Corporation.
Dr. Beckerle held a Guggenheim Fellowship at the Curie Institute in Paris, received the Utah Governor’s Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004 and is an elected Fellow of the American Academy of Arts and Sciences.
About Johnson & Johnson
Caring for the world, one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

###






Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings